GeekWire

NOVEMBER 9, 2023

Adaptive Biotechnologies CEO Chad Robins speaks at the GeekWire Summit in 2019. Adaptive’s net loss came in at $50.3 Adaptive reported third quarter revenue of $37.9 million, down 21% compared to the same period last year. Immune Medicine accounted for $13.3 million in revenue, down 52%. Meanwhile, MRD revenue was $24.7

Biotechnology 95

Biotechnology Real Estate .Net Conference 95

GeekWire

AUGUST 23, 2021

In the previous four years, Adaptive Biotechnologies was the only Washington state biotech company to go public. But now “investors are casting a wider net,” and “they recognize that there’s more out there,” according to Freedman, who is based in Fenwick’s San Francisco offices but also conducts business in Seattle.

Biotechnology 129

Biotechnology Company Trends Software 129

GeekWire

AUGUST 30, 2021

million net loss in 2020, doubling its annual revenue and cutting its loss nearly in half. million net loss in the first six months of this year. Other Washington state companies to go public this year include Eliem Therapeutics; Absci; Icosavax; Sana Biotechnology, Impel Neuropharma; and Paymentus.

Financial 130

Financial Biotechnology .Net Fashion 130

GeekWire

JUNE 30, 2021

The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Net losses were $14.4 Securities and Exchange Commission. 2020 revenue was $4.7 million, up from $2 million for 2019. 2020 revenue was $4.7

Company 131

Company Biotechnology .Net Programming 131

GeekWire

NOVEMBER 13, 2020

Adaptive Biotechnologies says it’s proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a study added to the evidence that its approach is more accurate than currently available antibody tests. Adaptive Biotechnologies Photo).

Biotechnology 137

Biotechnology Study Comparison .Net 137

GeekWire

MAY 12, 2020

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue , to nearly $21 million. The Seattle-based company posted a net loss of $31.4

Biotechnology 106

Biotechnology Pharmaceuticals .Net Microsoft 106

GeekWire

AUGUST 10, 2020

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

Biotechnology 102

Biotechnology Industry Research .Net 102

GeekWire

JULY 7, 2021

Pacific Northwest biotechs that have gone public this year include Sana Biotechnology, which raised $587 million in its February IPO and Impel NeuroPharma, which raised $80 million through its IPO in April. Net losses were $5.3 Icosavax has no revenue sources and has been operating at a loss. million in 2019 and $18.9

Development 142

Development Biotechnology Pharmaceuticals .Net 142

GeekWire

JULY 22, 2021

Absci joins several other Washington state biotechs that have gone public this year, including Sana Biotechnology , Impel Neuropharma , and Nautilus Biotechnology, which went public via a SPAC merger. Net losses were $14.4 The company’s revenue last year was $4.7 million, up from $2 million for 2019. million in 2019.

Company 129

Company Biotechnology .Net Development 129

GeekWire

SEPTEMBER 17, 2020

Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades. In its IPO paperwork, Athira reported a net loss of $5.2 million in 2019, and a loss of $3.8

Biotechnology 99

Biotechnology .Net Company Report 99

GeekWire

FEBRUARY 24, 2021

Seattle-based Adaptive Biotechnologies, which develops technology to sequence the human immune system to diagnose and treat disease, posted revenue of $30.2 The company’s quarterly net loss more than doubled to $44.6 million, and net loss grew to $146.2 Adaptive Biotech Graphic). million from $68.6 million a year earlier.

Company 118

Company Biotechnology .Net Research 118

GeekWire

AUGUST 26, 2020

The company, previously known as M3 Biotechnology, is led by Dr. Leen Kawas , a 35-year-old entrepreneur originally from Jordan. In its IPO paperwork, Athira reports a net loss of $5.2 It would be the first Seattle biotech to go public since Adaptive Biotechnologies IPO’d last year. million in 2019, and a loss of $3.8

Biotechnology 140

Biotechnology .Net Healthcare Development 140

GeekWire

SEPTEMBER 14, 2021

million net loss in the first six months of this year. million net loss in 2020, doubling its annual revenue and cutting its loss nearly in half. Sana Biotechnology had the largest to date in 2021, raising $587.5 The service eliminates forms, codes, and agents typically associated with the international money transfer process.

.Net 103

.Net Biotechnology Mobile Banking 103

GeekWire

DECEMBER 9, 2022

Seattle businesses including Porch, Nautilus Biotechnology, Rover and Leafly have all gone public via SPAC within the last two years. ” An investor presentation for the deal shows that Banzai posted a net loss of $8.5 More than 55 SPAC transactions have been called off this year and the traditional IPO market has also softened.

Company 101

Company Biotechnology Virtualization .Net 101

GeekWire

DECEMBER 27, 2022

He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. In Washington, Absci , Zymeworks , TwinStrand Biosciences , NanoString Technologies and Sana Biotechnology all shed employees in 2022. Sujal Patel has been here before. Nautilus CEO Sujal Patel. Nautilus Photo). Seagen Image).

Industry 114

Industry Biotechnology CTO Company 114

CTOvision

FEBRUARY 10, 2016

The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.

.Net 150

.Net Biotechnology Research Study 150

GeekWire

MARCH 17, 2023

Seagen reported $2 billion in revenue and a net loss of $610 million for 2022, along with $1.3 Lyell Immunopharma, Sana Biotechnology, Shape Therapeutics and a raft of other new companies were founded by veterans of Juno Therapeutics after its $9 billion acquisition by Celgene, cementing Seattle as a center for gene and cell therapy.

Biotechnology 108

Biotechnology .Net Research Conference 108

GeekWire

JUNE 24, 2020

million net loss and $132.5 million net loss and $94.8 Accolade would be the first Seattle-area company to go public since Adaptive Biotechnologies last year. It plans to trade on the Nasdaq exchange under the ticker ACCD. The company’s latest S-1 registration filing shows a $51.3 That’s compared to a $56.5

.Net 93

.Net Biotechnology Healthcare Financial 93

GeekWire

SEPTEMBER 23, 2021

It will raise more than $300 million in net proceeds as part of the IPO, one of the largest ever for a Seattle-area tech company. million net loss in the first six months of this year. million net loss in 2020, doubling its annual revenue and cutting its loss nearly in half. Remitly CEO Matt Oppenheimer. Remitly Photo).

Company 121

Company .Net Financial Mobile 121

GeekWire

SEPTEMBER 18, 2020

” Athira, previously known as M3 Biotechnology, plans to double the size of its 20-person team as it relocates into a larger facility in Bothell, Wash. In its IPO paperwork, Athira reported a net loss of $5.2 The company said it is committed to the local biotech and life sciences ecosystem. million in 2019, and a loss of $3.8

Biotechnology 102

Biotechnology Research Company .Net 102

Trends in the Living Networks

MARCH 23, 2011

Their joint work on a process for cloning genes in microorganisms resulted in three patents that formed the foundation of the nascent biotechnology industry. The agreement gave Buchwald a share of the film’s net profits, as defined in the contract. Be open throughout the process.

Open Source 138

Open Source Film Development Network 138

Trends in the Living Networks

AUGUST 11, 2022

Presentations and projects find her speaking to her interests, the importance of safe equanimity and its impact on the nexus of biotechnology and cultural design. She is a future thinker who specializes in the field of management and has launched more than 100 products, netting $18 billion in sales.

Study 148

Study Research Trends Education 148